The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.
For the Fourth Consecutive Year, NSH-BMT's One Year Related and Unrelated Allogeneic Transplant Survival Outcomes Were Among the Best in the U.S.1
Please go to Survival and Georgia Core: Center for Oncology Research & Education, http://www.georgiacore.org/articleDetail.aspx?articleID=317 , for additional information.
Atlanta Magazine Features NSH-BMT Program as Nominee for Groundbreaker of the Year for 2013
Atlanta Magazine has selected NSH-BMT as one of this year’s GroundBreaker of the year nominees. NSH-BMT Program and our patient, Bill Kahler, are featured in Atlanta Magazine’s November Groundbreaker edition. Bill underwent a haplo identical (half tissue match) allogeneic transplant where his son served as his donor. In collaboration with Johns Hopkins University’s Blood and Marrow Transplant Program, NSH-BMT has been a national leader in providing haploidentical transplants to those patients who do not have a full match related or unrelated allogeneic donor. NSH-BMT has organized their program to focus on factors that continuously produce outstanding survival outcomes; clinical research and quality.
NSH-BMT Collaborating with Dana-Farber Cancer Institute on Innovative Research Partnership
The Leukemia & Lymphoma Society (LLS) and the Dana-Farber Cancer Institute has established a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This groundbreaking Blood Cancer Research Partnership (BCRP), dana-farber.org/BCRP, will bring clinical trials closer to where patients live and help to address one of the primary bottlenecks in the development of new cancer therapies: the need for more patients to take part in trials. NSH-BMT is one of ten sites who have been selected to participate in this prestigious partnership.
LLS will be investing $1,050,000 in this three-year project. "This novel partnership between Dana-Farber Cancer Institute and LLS supports the mission of both organizations – to bring cutting-edge clinical research to a wider spectrum of patients with blood cancers today in order to change the paradigms of clinical care for patients tomorrow," said Blood Cancer Research Program Co-Director Robert Soiffer, M.D., who is the chief of the Division of Hematologic Malignancies at Dana-Farber. "The BCRP consortium will provide the opportunity for the Division of Hematologic Malignancies to extend clinical research trials to patients who are outside our regional area and do not have the capacity to come to Dana-Farber."
For more information about NSH-BMT’s collaboration with the Dana-Farber Cancer Institute, please call Stacey Brown, CCRP, Clinical Research & Data Supervisor, at 404-851-8238.
NSH- BMT featured on National Broadcast with Larry King
NSH-BMT was selected by In View productions to be featured in a national broadcast showcasing innovative medicine. The show is hosted by Larry King and was aired for national viewing on the Discovery Channel on May 15 at 7:00 AM EST. Please visit the links below to view the productions.
To view a more in depth video of the NSH-BMT program, click here
NSH-BMT Program is Now Enrolling to the Following Innovative Clinical Trial
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals: NSH IRB 959
Phase II BMT CTN multi-center trial to assess the feasibility and safety of reduced-intensity or fully-ablative allogeneic hematopoietic cell transplantation (HCT) in HIV-infected patients. 15 patients will be transplanted at multiple sites over two years. Where feasible, an attempt will be made to identify HLA-compatible hematopoietic stem cell donors who are homozygotes for the delta32 mutation of the chemokine receptor 5 (CCR5delta32). Patients will undergo a treatment plan review prior to registration on the trial. All patients will undergo allogeneic HCT from a matched sibling or unrelated donor. The physician will choose the regimen. This study is sponsored by NIH & BMT CTN. For additional study information and inclusion/exclusion criteria, please click here.
For more information, please call Stacey Brown, CCRP, Clinical Research & Data Supervisor at 404-851-8238.
NSH-Leukemia Program is Now Enrolling to the Following Innovative Clinical Trials
An Open-Label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22+ Acute Lymphoblastic Leukemia (ALL): NSH IRB 1011
An open label, mutli-center randomized (1:1) phase III study in patients with relapsed or refractory CD22+ ALL to determine the efficacy (defined as CR/CRi) of inotuzumab ozogamicin (Arm A) versus the investigator’s choice of chemotherapy (Arm B). At least 194 patients are expected to be randomized overall over approximately 26 months. The trial is sponsored by Pfizer and inotuzumab ozogamicin will be provided to the site. For additional study information and inclusion/exclusion criteria, please click here.
Phase III Randomized Clinical Trial of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: NSH 923
Phase III Randomized Trial of oral Sapacitabine/Decitabine vs. Decitabine only in elderly patients with newly diagnosed acute myeloid leukemia (AML).For additional study information and inclusion/exclusion criteria, please click here.
For more information, please call Stacey Brown, CCRP, Clinical Research & Data Supervisor at 404-851-8238.
National Marrow Donor Program (NMDP): Post Transplant Mobile App is Now Available
To help physicians with the reference materials they need to care for transplant patients, the NMDP has developed an app with leading transplant organizations to help increase survival rates. For more information, please go to Post BMT Discharge Instructions.
NSH-BMT Patient Asa Valente Meets Her Unrelated Donor at the
2012 BeTheMatch Tribute Dinner
On September 22, 2012, Asa Valente, a NSH-BMT patient who received primary leukemia treatment and an unrelated donor transplant in 2011, met her British donor, Edward Collier, at the 2012 BeTheMatch Tribute Dinner. Edward is a medical student who became involved in blood/marrow donor donation through a donor drive held at his medical school, Imperial College in London, England. Through his selfless generosity, Edward has given Asa a gift of a healthy and bright future.
Please click here to read more of Asa’s story,by Michelle Hiskey, or visit at Saportareport.com.
Dr. Asad Bashey, Northside Hospital's BMT-Program Clinical Research Medical Director, and a BMTGA Physician Published in the Peer Reviewed Journal: Journal of Clinical Oncology
In February 2013, Dr. Asad Bashey and colleagues had the following peer reviewed article published in the Journal of Clinical Oncology: T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation.
The Northside BMT Program is a national leader in performing allogeneic haploidentical transplants and has the best survival outcomes in the country. To read more about Dr. Bashey’s article, please click here.
Dr. Scott Solomon, Medical Director for the Northside Hospital’s Unrelated Donor Program and BMTGA Physician Published in the Peer Reviewed Journal: American Society for Blood and Marrow Transplantation
In December 2012, Dr. Scott Soloman and his colleagues had the following peer reviewed article published: Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial.
The Northside BMT Program is a national leader in performing allogeneic haploidentical transplants and has the best survival outcomes in the country. To read more about Dr. Solomon’s article, please log on to: www.asbmt.org and search under publications, Biology and Marrow Transplantation, Volume 18, Issue12, Pages 1859-1866, December 2012
NSH-BMT Program Named as Core Clinical Transplant Center
NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.
Join the Fight Against Cancer
By donating platelets and blood you can join the fight and directly impact the healthcare of patients being treated at NSH-BMT/Leukemia by donating with Atlanta Blood Services. To donate or find out additional information please go to http://www.atlantabloodservices.com/index.htm Or Click here to Like ABS on Facebook: http://www.facebook.com/atlantabloodservices
The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.